ERNA (Ernexa Therapeutics) Shares Outstanding (Diluted Average): 1.18 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ERNA Ernexa Therapeutics Inc ERNA
30 GF Score
Price $3.96
! 4 Warning Signs
View Full Analysis

What is Ernexa Therapeutics Shares Outstanding (Diluted Average)?

Ernexa Therapeutics ERNA +3.39% 30 Shares Outstanding (Diluted Average) is 1.18 Mil as of Jun. 2026. GuruFocus rates ERNA with a GF Score™ of 30/100. The stock has 4 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Ernexa Therapeutics's average diluted shares outstanding for the quarter that ended in Jun. 2026 was 1.18 Mil.


Ernexa Therapeutics  (NAS:ERNA) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Ernexa Therapeutics Shares Outstanding (Diluted Average) Related Terms


Ernexa Therapeutics Shares Outstanding (Diluted Average) Historical Data

* Premium members only.

The historical data trend for Ernexa Therapeutics's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ernexa Therapeutics Shares Outstanding (Diluted Average) Chart

Ernexa Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (Diluted Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.01 0.04 0.25

Ernexa Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shares Outstanding (Diluted Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.33 0.31 0.79 1.18
ERNA
30GF Score
Ernexa Therapeutics Inc ERNA
Shares Outstanding (Diluted Average) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ernexa Therapeutics Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (Diluted Average) of 1.18 Mil mean?
Ernexa Therapeutics (ERNA) has a Shares Outstanding (Diluted Average) of 1.18 Mil as of Jun. 2026. The average shares outstanding over two periods including dilutive securities like preferred shares and convertibles. View historical data on Ernexa Therapeutics and its competitors.
Is Ernexa Therapeutics' Shares Outstanding (Diluted Average) too high?
Ernexa Therapeutics' current Shares Outstanding (Diluted Average) is 1.18 Mil. Overall, Ernexa Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Ernexa Therapeutics' Shares Outstanding (Diluted Average) compare to CDIO and LABT?
Ernexa Therapeutics' Shares Outstanding (Diluted Average) of 1.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (Diluted Average) for a Biotechnology company?
A good Shares Outstanding (Diluted Average) depends on the Biotechnology industry context. However, Shares Outstanding (Diluted Average) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (Diluted Average) mean?
A high Shares Outstanding (Diluted Average) can signal that a stock is expensive relative to its fundamentals. The average shares outstanding over two periods including dilutive securities like preferred shares and convertibles. View historical data on Ernexa Therapeutics and its competitors. Ernexa Therapeutics's current Shares Outstanding (Diluted Average) is 1.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ernexa Therapeutics stock overvalued right now?
Ernexa Therapeutics (ERNA) has a current Shares Outstanding (Diluted Average) of 1.18 Mil. The current Shares Outstanding (Diluted Average) is 1.18 Mil. Ernexa Therapeutics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (Diluted Average) calculated?
Shares Outstanding (Diluted Average) is calculated from a company's financial statements. For Ernexa Therapeutics (ERNA), the current Shares Outstanding (Diluted Average) is 1.18 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ernexa Therapeutics Business Description

Address 1035 Cambridge Street, Suite 18A, Cambridge, MA, USA, 02141
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
30GF Score

Get the complete analysis for ERNA

Shares Outstanding (Diluted Average) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.96
Price